Find a Doctor »Your Treatment Team »Medical Oncology

« More

Publications

» Articles » Chapters » Abstracts

Select Peer Reviewed Publications
Since 2004

Bepler G, Sharma S, Cantor A, Gautam A, Haura E, Simon GR, Sharma A, Sommers E and Robinson L. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with Non-Small Cell Lung Cancer.
Journal of Clinical Oncology. 2004: 22(10): 1878-1885.

Nordquist LT, Simon GR, Cantor AB, Alberts WM and Bepler G.  Improved Survival in Never-Smokers versus Current Smokers with Primary Adenocarcinoma of the Lung.
Chest 2004: 126: 347-351.
Accompanying Editorial on the above article: Mazzone PJ, Mikhail T, Arroliga AC. Is lung cancer in the non-smoker a different disease?
Chest 2004: 126: 326- 329.

Simon GR, Sharma S, Cantor A, Smith P, Alberts WM and Bepler G.
ERCC1 Expression is a Predictor of Survival in Resected Patients with Non-Small-Cell Lung Cancer (NSCLC).
Chest 2005: 127(3): 978-983.

Chiappori A, Simon GR, Williams C, Haura E, Rocha-Lima C, Wagner H, Bepler G, Antonia S. Phase II Study of First-line Sequential Chemotherapy with Gemcitabine-Carboplatin followed by Docetaxel in patients with Advanced Non-Small Cell Lung Cancer.
Oncology 2005: 68(4-6): 382-390.

Fishman MN, Garrett CR, Simon GR, Chiappori AA, Lush RM, Dinwoodie WR, Mahany JJ, Dellaportes AM, Cantor A, Gollerki A, Cohen MB and Sullivan DM.
Phase I Study of the taxane BMS-188707 in combination with carboplatin administered every 3 weeks in patients with solid malignancies.
Clinical Cancer Research. 2006 Jan 15; 12(2):523-528.

Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N, Bepler G, Simon GR, Janssen W, Lee JH, Menander K, Chada S and Gabrilovich DI.
Combination of p53 Cancer Vaccine with chemotherapy in patients with extensive stage small cell lung cancer.
Clinical Cancer Research. 2006 Feb; 12(3):878-887

Simon GR, Lush RM, Gump J, Tetteh L, Williams C, Cantor A, Antonia S, Garrett C, Rocha-Lima C, Fishman M, Sullivan DM, Munster PN. Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial.
Molecular Cancer Therapeutics. 2006 Aug; 5(8):2130-7.

Simon GR, Garrett CR, Olson SC, Langevin M, Eiseman IA, Mahany JJ, William CC, Lush R, Daud A, Munster P, Chiappori A, Fishman M, Bepler G, Lenehan PF, Sullivan DM. Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study.
Clinical Cancer Research. 2006 Aug 1; 12(15):4645-51

Bepler G, Kusmartseva I, Gautam A, Sharma S, Cantor A, Sharma A and Simon GR.
RRM1-Modulated In Vitro and In Vivo Efficacy of Gemcitabine and Platinum in Non-Small Cell Lung Cancer. Journal of Clinical Oncology. 
Journal of Clinical Oncology.  Oct 10; 24(29):4731-7.  2006.

Cohen RB, Langer CJ, Simon GR, Eisenberg PD, Hainsworth JD, Madajewicz, Cosgriff TM, Pierce K, Noe DA, Liau K and Healey D. A phase I /randomized phase II, non-comparative, multicenter, open label trial of CP-547-632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lug cancer (NSCLC).
Cancer Chemotherapy Pharmacology.  2007 Jun; 60(1): 81-9.

de Lima Lopes G, Chiappori A, Simon GR, Haura E, Sullivan D, Antonia S, Langevin M, Lush, R, Rocha-Lima CM. 
Phase I Study of Carboplatin in Combination with Gemcitabine and Irinotecan in Patients with Solid Tumors:  Preliminary Evidence of Activity in Small Cell and Neuroendocrine Carcinomas. 
Cancer. 2007 Apr 1; 109(7): 1413-9.

Fracasso PM, Burris H, Arquette MA, Govindan R, Gao F, Wright LP, Goodner SA, Jones SF, Willcut N, CXhodkiewicz C, Pathak A, Springett GM, Simon GR, Sullivan DM, Marcepoil R, Mayfield SD, Mauro D, and Garrett CR.  Phase I Study of single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing.
Clinical Cancer Research. 2007. Feb 1; 13(3): 980-93. 

Munster PN, Marchion D, Bicaku E, Schmitt M, Deconti R, Simon GR, Fishman M, Minton S, Garrett C, Chiappori A, Lush R, Sullivan D and Daud A. Phase I Trial of histone deacytylase inhibition by valproic acid (VPA) followed by topoisomerase II inhibition with epirubicin in advanced solid tumors: a clinical and Translational Study.
Journal of Clinical Oncology.  2007 May 20; 25(15): 1979-1985.

Homsi J, Simon GR, Garrett CR, Springett G, DeConti R, Chiappori A, Munster PN, Burton M, Stromatt S, Allievi C, Bernareggi B, Sullivan D, and Daud AI. Phase I trial of Poly L-glutamated camptothecin (CT2106) administered weekly in patients with advanced solid malignancies.
Clinical Cancer Research. 2007 Oct 1; 13(19): 5855-61.

Simon GR and Turrissi A., Small Cell Lung Cancer: An Evidence Based Guideline.
Chest 2007. Sept: 132(3 Suppl): 324S-339S.

Samson DJ, Seidenfeld J, Simon GR, Aurrisi AT, Bonnell C, Ziegler KM and Aronson N., Evidence of management of small cell lung cancer: ACCP evidence-based clinical practive guidelines (2nd edition)
Chest 2007 Sept; 132 (3Suppl): 314S-323S. 

Simon GR, Sharma A, Xueli L, Hazelton, T, Walsh F, Williams C, Chiappori A, Haura E, Tanvetyanon T, Antonia S, Cantor A and Bepler G., Feasibility and Efficacy of Molecular Analyses-Directed Individualized Therapy in Advanced Non-Small Cell Lung Cancer.
Journal of Clinical Oncology. 2007 Jul 1; 25 (19): 2741-6.

Simon GR, Begum M, Ismail-Khan R, and Bepler G. , DNA Repair and Chemotherapy for Lung Cancer. 
International Journal of Biochem & Cell Biol. 2007; 39(7-8): 1318-28.

Rastogi S, Chellapan S and Simon GR.
Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines.
Cancer Letters. 2007 (Nov) 18; 257(2): 224-51.

Chiappori AA, Haura E, Rodriguez FA, Boulware D, Kapoor R, Neuger AM, Lush R, Padilla B, Burton M, Williams CC, Simon GR, Antonia S, Sullivan DM and Bepler G., Phase I/II study of Atrasentan , and Endothelin A receptor antagonist in combination with Paclitaxel and Carboplatin as First-line Therapy in Advanced Non-Small Cell Lung Cancer.
Clinical Cancer Research 2008. Mar 1; 14(5): 1464-9

Simon GR, Extermann M, Chiappori A, Williams CC, Begum M, Kapoor R, Haura EB, Ismail-Khan R, Schell MJ, Antonia SJ and Bepler G. Phase II trial of docetaxel and gefitinib in the first-line treatment of patients with advanced stage non-small cell lung cancer (NSCLC) who are 70 years or age or older.
Cancer 2008  May 1; 112(9): 2021-9
 
Janne PA, Simon GR, Langer CJ, Taub RN, Dowlati A, Fidias P, Monberg M, Obasaju C and Kindler H. Phase II trial of pemetrexed and gemcitabine in chemotherapy-naïve malignant pleural mesothelioma.
Journal of Clinical Oncology, 2008 Mar 20; 26(9): 1465-71.

Simon GR, Verschraegen CF, Janne PA, Langer CJ, Dowlati A, Gadgeel S, Kelly K, Kalemkerian G, Traynor A, Peng G, Gill J, Obasaju CK and Kindler HL., Pemetrexed plus Gemcitabine as Front-line chemotherapy for patients with Peritoneal Mesothelioma: Final Report of a phase II Trial.
Journal of Clinical Oncology 2008 Jul 20; 26(21):3567-72.

Bepler G, Sommers KE, Cantor A, Li X, Sharma A, Williams C, Chiappori A, Haura E, Antonia S, Tanvetyanon T, Simon GR, Obasaju C, Robinson LA. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer.
J Thorac Oncol. 2008 Oct;3(10):1112-8

Video

Introductory Video of Dr. Simon

Medical Oncology

Director of Thoracic Oncology,
Department of Medical Oncology

Meet the other members of the
lung cancer treatment team.

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111-2497

New patients can request an appointment online or call 215-728-2570.

Appointments for Returning Patients

For general information, call:
1-888-FOX CHASE (1-888-369-2427).
An oncology certified nurse will assist you.

Clinical Expertise:

Lung Cancer and Mesothelioma

Medical Education:

MB, BS, Christian Medical College and Hospital, Ludhiana, Punjab India, 1986

Residency:

St. Joseph’s Hospital, Denver CO;
Christian Medical College and Hospital, Ludhiana, Punjab India

Fellowships:

Medical Oncology and Hematology, University of Colorado Health Sciences Center, Denver CO.

Certifications:

American Board of Internal Medicine;
Medical Oncology;
Hematology

Professional Societies:

Invited Member, Thoracic Core Committee of the Eastern Cooperative Oncology Group (ECOG);
Fellow, American College of Physicians (ACP);
Fellow, American College of Chest Physicians (ACCP);
Member, American Academy of Advancement of Science (AAAS);
Member, American Association for Cancer Research (AACR);
Member, American Society of Clinical Oncology (SCO);
Member, International Association for the Study of Lung Cancer (IASLC);

Awards:

See List.

Research Interests:

Nuclear excision repair; Personalizing chemotherapy for Non-Small Cell Lung Cancer and Glucose metabolism in tumors